# Inventera

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/inventera

- Industry: Biotechnology
- Headquarters: Seoul, South Korea
- Website: www.inventera.kr/
- Total disclosed funding: $25M
- Latest round: Series C (Oct 29, 2024)
- Investors on record: 11

## About

Based in South Korea, Inventera Inc. is a biotechnology company that specializes in developing innovative nanomedicine solutions for therapeutic applications.Inventera Inc. was founded in 2018 and is headquartered in Seoul, South Korea. The company focuses on the creation and commercialization of its nanomedicine platform, Invinity™, designed for therapeutic advancements. The founder, Tae-hyun Shin, has a background in biotechnology and leads the company as CEO. Inventera has completed a total of 5 deals, with its most recent deal occurring on April 2, 2026. The company raised KRW 18.5 billion in its Series C funding round, supported by a consortium of various investors, including Chungbuk Creative Economy Innovation Center and NH Investment & Securities.Inventera operates primarily through its innovative nanomedicine platform, Invinity™, which is designed for the development and commercialization of first-in-class therapeutics. This platform encompasses a range of applications, from diagnostic imaging agents to next-generation therapies, focusing on optimizing drug circulation time within the body to enhance efficacy. Invinity™ allows for targeted delivery of medications to specific tissues, improving therapeutic effects and reducing side effects. The company’s technology is backed by a robust global intellectual property portfolio, with applications across North America, Europe, and Asia, serving pharmaceutical companies and healthcare practitioners as core clients.Inventera's revenue model is structured around partnerships and collaborations with pharmaceutical firms and healthcare institutions, focusing on the commercialization of its Invinity™ platform products. Business transactions typically occur through contractual agreements for the development and licensing of its technologies, facilitating integration into clients' offerings. The financial structure includes upfront licensing fees, milestone payments based on development achievements, and royalties on future sales of products utilizing the Invinity™ platform.Inventera plans to launch new products designed around its Invinity™ platform, with specific release dates to be determined as development progresses. The company is targeting expansion into additional markets in North America and Europe by 2027. The recent funding raised of KRW 18.5 billion will support these initiatives, particularly the upcoming IPO on April 2, 2026, where Inventera sold 1.18 million shares at KRW 16,600 each, within the expected price range.

## Funding rounds

- Series C, Oct 29, 2024, $13M — WOORI Venture Partners, Yuanta Investment, NH Investment & Securities, Evergreen Investment Partners, Eugene Investment & Securities, Medytox Venture Investment, Chungbuk Creative Economy Innovation Center
- Series B, Sep 8, 2022, $7.4M — IMM Investment, BNK Venture Capital, Evergreen Investment Partners, Eugene Investment & Securities, Medytox Venture Investment, DAOL Investment & Securities, LITEPHARMTECH Co., Ltd.
- Series A, Aug 30, 2020, $4.2M — Medytox Venture Investment, DAOL Investment & Securities
- Angel, Nov 20, 2018, $0.1M — Chungbuk Creative Economy Innovation Center

## Investors

- Chungbuk Creative Economy Innovation Center (https://capitalatlas.ai/funds/chungbuk-creative-economy-innovation-center) — Angel, Series C
- Medytox Venture Investment (https://capitalatlas.ai/funds/medytox-venture-investment) — Series A, Series B, Series C
- DAOL Investment & Securities — Series A, Series B
- IMM Investment (https://capitalatlas.ai/funds/imm-investment) — Series B
- BNK Venture Capital (https://capitalatlas.ai/funds/bnk-venture-capital) — Series B
- Evergreen Investment Partners (https://capitalatlas.ai/funds/evergreen-investment-partners) — Series B, Series C
- Eugene Investment & Securities — Series B, Series C
- LITEPHARMTECH Co., Ltd. — Series B
- WOORI Venture Partners (https://capitalatlas.ai/funds/woori-venture-partners) — Series C
- Yuanta Investment (https://capitalatlas.ai/funds/yuanta-investment) — Series C
- NH Investment & Securities (https://capitalatlas.ai/funds/nh-investment-securities) — Series C